Oral Capecitabine for the Treatment of Hepatocellular Carcinoma, Cholangiocarcinoma, and Gallbladder Carcinoma

摘要: BACKGROUND The goal of the current study was to evaluate efficacy and toxicity capecitabine in patients with nonresectable hepatobiliary carcinoma. METHODS The authors performed a retrospective analysis all hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), or gallbladder (GBC) who were ever treated oral capecitabine. The medical records 116 at University Texas M. D. Anderson Cancer Center (Houston, TX) between July 1998 March 1999 reviewed. RESULTS A total 63 (37 HCC, 18 CCA, 8 GBC). Capecitabine 1000 mg/m2 administered twice daily for 14 days. Treatment repeated every 21 Each patient received 1–15 treatment cycles. Nine (14%)—11% 6% 50% GBC—had either complete response (CR) partial response. A CR radiologically confirmed one HCC two GBC. median survival times 10.1 months (95% confidence interval [CI], 4.5–15.7 months) 8.1 CI, 7.4–8.9 9.9 4.4–15.4 most common hand-foot syndrome (37%). Grade 3 thrombocytopenia occurred 8% HCC. No other significant toxicities observed. For patients, positively correlated decline tumor markers. CONCLUSIONS Capecitabine found be safe carcinoma, including those cirrhosis. antitumor activity single-agent pronounced GBC, modest poor CCA. 2004. © 2004 American Society.